CSIMarket
 
Rhythm Pharmaceuticals inc   (RYTM)
Other Ticker:  
 
 
Price: $40.6000 $0.60 1.500%
Day's High: $41.0475 Week Perf: 1.05 %
Day's Low: $ 39.74 30 Day Perf: -19.56 %
Volume (M): 481 52 Wk High: $ 52.57
Volume (M$): $ 19,512 52 Wk Avg: $28.03
Open: $40.00 52 Wk Low: $15.50



 Market Capitalization (Millions $) 2,350
 Shares Outstanding (Millions) 58
 Employees -
 Revenues (TTM) (Millions $) 69
 Net Income (TTM) (Millions $) -203
 Cash Flow (TTM) (Millions $) -120
 Capital Exp. (TTM) (Millions $) 6

Rhythm Pharmaceuticals Inc
Rhythm Pharmaceuticals Inc. is a biopharmaceutical company that focuses on developing therapies for rare genetic disorders of obesity. The company is committed to addressing the unmet medical needs of patients with these conditions and aims to improve their quality of life. Rhythm Pharmaceuticals utilizes a precision medicine approach to develop innovative therapies that target specific genetic mutations causing obesity-related disorders. Their research and development efforts are centered around a pipeline of potential treatments that aim to restore metabolic balance and help patients achieve sustainable weight loss and improvement in their overall health.


   Company Address: 222 Berkeley Street Boston 2116 MA
   Company Phone Number: 264-4280   Stock Exchange / Ticker: NASDAQ RYTM
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Stock Market Announcement

Rhythm Pharmaceuticals' Employment Inducement Grants Pave the Way for Promising Growth

Published Mon, Mar 11 2024 8:01 PM UTC



Rhythm Pharmaceuticals, a renowned biopharmaceutical company dedicated to transforming the lives of patients battling rare neuroendocrine diseases, has recently made a significant announcement. On March 6, 2024, the Compensation Committee of Rhythm's board of directors granted inducement equity grants to three new employees. These grants encompassed 13,780 shares o...

Clinical Study

Rhythm Pharmaceuticals Takes on Hypothalamic Obesity in Japan: Expanding Clinical Development Plan for Setmelanotide

Published Thu, Feb 22 2024 12:01 PM UTC

Rhythm Pharmaceuticals Expands Clinical Development Plan for Setmelanotide in JapanRhythm Pharmaceuticals has recently announced the expansion of its clinical development plan for Setmelanotide in Japan, specifically targeting patients suffering from hypothalamic obesity. This development comes as a response to the significant unmet need in Japan, with an estimated 5,000 to ...

Management Announcement

Rhythm Pharmaceuticals Grants Employment Inducement Equity to Stimulate Growth and Drive Innovation.

Published Thu, Feb 8 2024 9:01 PM UTC

Rhythm Pharmaceuticals Grants Employment Inducement Equity to Drive Growth and Innovation
Summary:
Rhythm Pharmaceuticals, a commercial-stage biopharmaceutical company specializing in rare neuroendocrine diseases, has announced the issuance of employment inducement grants to new employees. These grants include stock options and restricted stock units, showing the co...

Management Announcement

Rhythm Pharmaceuticals Empowers Growth and Innovation with Substantial Inducement Grants to New Talent

Published Fri, Jan 12 2024 9:01 PM UTC


Rhythm Pharmaceuticals, a leading biopharmaceutical company dedicated to improving the lives of patients and families facing rare neuroendocrine diseases, recently announced the issuance of employment inducement grants to four highly skilled individuals. These grants, which comprise inducement stock options and restricted stock units (RSUs), signify the company's commit...

Clinical Study

LB54640: A Targeted Oral MC4R Agonist Advancing the Treatment Landscape for Metabolic Disorders

Published Thu, Jan 4 2024 12:01 PM UTC

In an exciting development in the field of metabolic disorders, Rhythm Pharmaceuticals has recently entered into an agreement with LG Chem Life Sciences to acquire global rights to the oral MC4R agonist LB54640. This novel therapy has shown a targeted effect on the MC4 receptor without the side effect of hyperpigmentation. Rhythm Pharmaceuticals is set to advance LB54640 in ...






 

Rhythm Pharmaceuticals Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com